rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
1
|
pubmed:dateCreated |
2003-7-9
|
pubmed:abstractText |
Steroid resistance represents a major clinical problem in the treatment of ulcerative colitis. In vitro, interleukin-2 renders lymphocytes steroid resistant.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0269-2813
|
pubmed:author |
pubmed-author:AndersonJJ,
pubmed-author:CreedT JTJ,
pubmed-author:DayanC MCM,
pubmed-author:GuptaJJ,
pubmed-author:HarveyR FRF,
pubmed-author:HearingS DSD,
pubmed-author:MoorghenMM,
pubmed-author:NormanM RMR,
pubmed-author:ProbertC S JCS,
pubmed-author:ShawI SIS,
pubmed-author:ShepherdN ANA,
pubmed-author:SmithsonJJ
|
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
18
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
65-75
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:12848627-Adult,
pubmed-meshheading:12848627-Aged,
pubmed-meshheading:12848627-Antibodies, Monoclonal,
pubmed-meshheading:12848627-Colitis, Ulcerative,
pubmed-meshheading:12848627-Drug Combinations,
pubmed-meshheading:12848627-Drug Resistance,
pubmed-meshheading:12848627-Female,
pubmed-meshheading:12848627-Humans,
pubmed-meshheading:12848627-Immunosuppressive Agents,
pubmed-meshheading:12848627-Male,
pubmed-meshheading:12848627-Middle Aged,
pubmed-meshheading:12848627-Recombinant Fusion Proteins,
pubmed-meshheading:12848627-Remission Induction,
pubmed-meshheading:12848627-Steroids,
pubmed-meshheading:12848627-Treatment Outcome
|
pubmed:year |
2003
|
pubmed:articleTitle |
Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis.
|
pubmed:affiliation |
University Research Centre for Neuroendocrinology, Bristol Royal Infirmary, Bristol, UK.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|